Ignite Creation Date:
2025-12-24 @ 8:01 PM
Ignite Modification Date:
2025-12-25 @ 5:34 PM
Study NCT ID:
NCT00062504
Status:
TERMINATED
Last Update Posted:
2011-05-23
First Post:
2003-06-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-07
Start Date Type:
None
Primary Completion Date:
2006-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2006-04
Completion Date Type:
ACTUAL
First Submit Date:
2003-06-06
First Submit QC Date:
None
Study First Post Date:
2003-06-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-05-20
Last Update Post Date:
2011-05-23
Last Update Post Date Type:
ESTIMATED